Latest Period
Q1 2026
Security Snapshot
CYTOKINETICS INC - COMMON STOCK (CYTK) Institutional Ownership
CUSIP: 23282W605
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
437
Shares (Excl. Options)
146,063,255
Price
$65.91
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- CYTK on Nasdaq
- Shares outstanding
- 123,724,358
- Reported price per share
- $77.22
- Price from insider filings
- $77.22
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 146,063,255
- Total reported value
- $9,622,857,226
- Portfolio coverage rank
- 0.01%
- Share change
- +6,087,955
- Value change
- +$407,609,732
- Number of holders
- 437
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- CYTK - CYTOKINETICS INC - COMMON STOCK is tracked under CUSIP 23282W605.
- 437 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 430 to 437 between Q4 2025 and Q1 2026.
- Reported value moved from $8,860,425,548 to $9,622,857,226.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 437 institutions filings for Q1 2026.
Security key
23282W605
Latest holder period
Q1 2026
13F holders
437
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
CYTK full holder history
CYTOKINETICS INC SEC filings
CYTOKINETICS INC company facts
CYTOKINETICS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23282W605:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
CYTK
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14% | -9.4% | $1,145,186,286 | -$89,267,905 | 17,716,372 | -7.2% | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 |
| FMR LLC | 9% | -17% | $742,940,026 | -$131,198,475 | 11,135,192 | -15% | FMR LLC | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $423,276,788 | 6,422,042 | Vanguard Capital Management | 31 Mar 2026 | |||
| STATE STREET CORP | 4.7% | $308,728,677 | 5,617,334 | STATE STREET CORPORATION | 30 Sep 2025 |
As of 31 Mar 2026, 437 institutional investors reported holding 146,063,255 shares of CYTOKINETICS INC - COMMON STOCK (CYTK). This represents 118% of the company’s total 123,724,358 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
83%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14% | 17,523,840 | -1.1% | 0.8% | $1,154,997,000 |
| BlackRock, Inc. | 13% | 16,548,011 | +0.93% | 0.02% | $1,090,679,433 |
| FMR LLC | 8.7% | 10,723,140 | -16% | 0.04% | $706,762,165 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.5% | 8,009,489 | +0.91% | 0.1% | $527,905,420 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7% | 5,843,782 | 0% | 0.02% | $385,163,672 |
| STATE STREET CORP | 4.6% | 5,745,193 | -1.4% | 0.01% | $378,665,671 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 5,488,634 | 0% | 0.01% | $361,755,867 |
| Avoro Capital Advisors LLC | 2.7% | 3,333,333 | 2.2% | $219,699,978 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 3,215,415 | +5.2% | 0.01% | $211,965,492 |
| BANK OF AMERICA CORP /DE/ | 2.5% | 3,125,436 | +6.3% | 0.02% | $205,997,488 |
| RTW INVESTMENTS, LP | 2.2% | 2,721,158 | 0% | 1.8% | $179,351,524 |
| GOLDMAN SACHS GROUP INC | 1.8% | 2,205,758 | -7% | 0.02% | $145,381,509 |
| UBS Group AG | 1.7% | 2,077,277 | +84% | 0.02% | $136,913,327 |
| Polar Capital Holdings Plc | 1.3% | 1,661,248 | -31% | 0.48% | $109,492,856 |
| Integral Health Asset Management, LLC | 1.3% | 1,600,000 | +14% | 5.6% | $105,456,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.3% | 1,584,321 | -18% | 0.01% | $104,424,000 |
| MORGAN STANLEY | 1.2% | 1,505,075 | +19% | 0.01% | $99,199,590 |
| Paradigm Biocapital Advisors LP | 1.2% | 1,480,857 | 2% | $97,603,285 | |
| NORTHERN TRUST CORP | 1.2% | 1,441,634 | +4.4% | 0.01% | $95,018,097 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.1% | 1,397,045 | +0.98% | 0.01% | $92,079,236 |
| Deep Track Capital, LP | 1.1% | 1,374,320 | -59% | 1.9% | $90,581,431 |
| Capital International Investors | 1.1% | 1,338,803 | +14% | 0.02% | $88,240,506 |
| Frazier Life Sciences Management, L.P. | 0.94% | 1,159,879 | +24% | 2% | $76,447,625 |
| CITADEL ADVISORS LLC | 0.89% | 1,099,858 | -5.4% | 0.05% | $72,491,641 |
| PRINCIPAL FINANCIAL GROUP INC | 0.88% | 1,093,485 | +12% | 0.04% | $72,071,596 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 146,063,255 | $9,622,857,226 | +$407,609,732 | $65.91 | 437 |
| 2025 Q4 | 139,444,813 | $8,860,425,548 | -$178,120,443 | $63.54 | 430 |
| 2025 Q3 | 140,922,555 | $7,744,502,918 | +$248,284,955 | $54.96 | 379 |
| 2025 Q2 | 137,672,960 | $4,548,776,123 | +$22,757,186 | $33.04 | 308 |
| 2025 Q1 | 134,841,578 | $5,424,137,644 | +$124,956,259 | $40.19 | 352 |
| 2024 Q4 | 131,310,237 | $6,182,701,180 | -$305,419,938 | $47.04 | 342 |
| 2024 Q3 | 135,965,538 | $7,179,495,863 | -$22,095,980 | $52.80 | 343 |
| 2024 Q2 | 135,538,659 | $7,341,546,249 | +$905,298,022 | $54.18 | 341 |
| 2024 Q1 | 117,698,153 | $8,252,737,252 | +$191,436,420 | $70.11 | 385 |
| 2023 Q4 | 114,281,648 | $9,541,763,681 | +$330,415,688 | $83.49 | 344 |
| 2023 Q3 | 109,279,375 | $3,219,564,491 | +$24,845,219 | $29.46 | 248 |
| 2023 Q2 | 108,724,328 | $3,548,383,679 | -$11,513,808 | $32.62 | 252 |
| 2023 Q1 | 108,867,212 | $3,829,923,005 | +$81,444,143 | $35.19 | 259 |
| 2022 Q4 | 106,503,991 | $4,877,881,469 | +$56,105,064 | $45.82 | 271 |
| 2022 Q3 | 104,802,748 | $5,076,619,614 | -$48,250,542 | $48.45 | 271 |
| 2022 Q2 | 105,856,945 | $4,159,716,153 | +$425,134,262 | $39.29 | 255 |
| 2022 Q1 | 95,536,900 | $3,516,647,768 | +$153,742,395 | $36.81 | 233 |
| 2021 Q4 | 91,314,688 | $4,159,253,639 | +$41,291,377 | $45.58 | 244 |
| 2021 Q3 | 90,207,271 | $3,220,707,699 | +$496,552,275 | $35.74 | 208 |
| 2021 Q2 | 75,530,208 | $1,494,840,686 | +$7,258,934 | $19.79 | 184 |
| 2021 Q1 | 74,824,822 | $1,739,406,944 | +$58,909,832 | $23.26 | 185 |
| 2020 Q4 | 72,927,397 | $1,515,101,565 | +$2,994,280 | $20.78 | 174 |
| 2020 Q3 | 68,793,341 | $1,486,919,340 | +$223,796,678 | $21.65 | 176 |
| 2020 Q2 | 57,902,469 | $1,364,739,639 | +$106,180,554 | $23.57 | 155 |
| 2020 Q1 | 55,577,469 | $655,114,415 | +$7,494,589 | $11.79 | 140 |